Paradox breaker BRAF inhibitors have comparable potency and MAPK pathway reactivation to encorafenib in BRAF mutant colorectal cancer

Overview of attention for article published in Oncotarget, August 2020

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (90th percentile)
Average Attention Score compared to outputs of the same age and source

Mentioned by

news: 2 news outlets
blogs: 1 blog

twitter: 5 X users
facebook: 1 Facebook page

Citations

dimensions_citation: 10 Dimensions

Readers on

mendeley: 18 Mendeley

Summary News Blogs X Facebook Dimensions citations

So far, Altmetric has seen 5 X posts from 5 X users, with an upper bound of 5,255 followers.

Paradox breaker BRAF inhibitors have comparable potency and MAPK pathway reactivation to encorafenib in BRAF mutant ... https://t.co/LpTANvuSeB

26 Oct 2020

Reply Repost Favourite

RT @Oncotarget: The cover for issue 34 of @Oncotarget features Figure 1, "BRAF inhibitor-induced changes in cell viability," by Pickles, et…

26 Aug 2020

Reply Repost Favourite

RT @Oncotarget: The cover for issue 34 of @Oncotarget features Figure 1, "BRAF inhibitor-induced changes in cell viability," by Pickles, et…

26 Aug 2020

Reply Repost Favourite

RT @Oncotarget: The cover for issue 34 of @Oncotarget features Figure 1, "BRAF inhibitor-induced changes in cell viability," by Pickles, et…

26 Aug 2020

Reply Repost Favourite

The cover for issue 34 of @Oncotarget features Figure 1, "BRAF inhibitor-induced changes in cell viability," by Pickles, et al. https://t.co/VmY2XOrs60

26 Aug 2020

Reply Repost Favourite

Oncotarget

Article Metrics

Paradox breaker BRAF inhibitors have comparable potency and MAPK pathway reactivation to encorafenib in BRAF mutant colorectal cancer

About this Attention Score

Mentioned by

Citations

Readers on